Kisqali Femara Co-pack Kit
Product Images NDC 0078-0916

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Kisqali Femara Co-pack (NDC 0078-0916). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Kaplan-meier Progression Free Survival Curves – Monaleesa-2 (intent-to-treat Population) (Figure1)

This chart shows the Eventree probability percentage (%) at various censoring times (in months) for 334 individuals taking Ribociclib and 334 individuals taking a placebo. The percentages are displayed at the intervals of 100, 60, 40, and 20.*

FDA Label Image

Figure 2 Kaplan-meier Progression Free Survival Curves – Monaleesa-7 (nsai, Investigator Assessment) (Figure2)

This appears to be a table displaying data related to a study involving a cancer treatment (Rboocib) and a control group (Placsbo) over a period of two years. The table includes information regarding the number of patients at risk and the number of patients who survived at various time points during the study.*

FDA Label Image

Figure 3 Kaplan-meier Overall Survival Curves- Monaleesa-7 (nsai) (Figure3)

This appears to be a graphical representation of data from a clinical trial comparing the effectiveness of a drug called Ribocidib versus a placebo in treating an illness. The vertical axis may represent the number of patients still at risk of the illness, while the horizontal axis represents the time elapsed in months. There may have been a total of 248 patients receiving Ribocidib and 247 patients receiving the placebo in the trial. However, without more information, it is difficult to provide a detailed interpretation of the data.*

FDA Label Image

Principal Display Panelkisqali Femara Co-pack(ribociclib And Letrozole) Tablets200 mg Daily Dose (one 200 mg Tablet) 21 Film-coated Tablets2.5 mg Per Tablet 28 Film-coated Tablets28-day Supplyndc 0078-0909-61rx Only (Kisqali Femara 01)

FDA Label Image

Principal Display Panelkisqali Femara Co-pack(ribociclib And Letrozole) Tablets400 mg Daily Dose (two 200 mg Tablets) 42 Film-coated Tablets2.5 mg Per Tablet 28 Film-coated Tablets28-day Supplyndc 0078-0916-61rx Only (Kisqali Femara 02)

FDA Label Image

Principal Display Panelkisqali Femara Co-pack(ribociclib And Letrozole) Tablets600 mg Daily Dose (three 200 mg Tablets) 63 Film-coated Tablets2.5 mg Per Tablet 28 Film-coated Tablets28-day Supplyndc 0078-0923-61rx Only (Kisqali Femara 03)

FDA Label Image

Letrozole Structure (Letrozole Structure)

FDA Label Image

Ribociclib Structure (Ribociclib Structure1)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.